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Abstract
A World Antimalarial Resistance Network (WARN) database has the potential to improve the treatment of malaria,
through informing current drug selection and use and providing a prompt warning of when treatment policies need
changing. This manuscript outlines the contribution and structure of the clinical pharmacology component of this
database. The determinants of treatment response are multi-factorial, but clearly providing adequate blood
concentrations is pivotal to curing malaria. The ability of available antimalarial pharmacokinetic data to inform optimal
dosing is constrained by the small number of patients studied, with even fewer (if any) studies conducted in the most
vulnerable populations. There are even less data relating blood concentration data to the therapeutic response
(pharmacodynamics). By pooling all available pharmacokinetic data, while paying careful attention to the analytical
methodologies used, the limitations of small (and thus underpowered) individual studies may be overcome and factors
that contribute to inter-individual variability in pharmacokinetic parameters defined. Key variables for pharmacokinetic
studies are defined in terms of patient (or study subject) characteristics, the formulation and route of administration of
the antimalarial studied, the sampling and assay methodology, and the approach taken to data analysis. Better defining
these information needs and criteria of acceptability of pharmacokinetic-pharmacodynamic (PK-PD) studies should
contribute to improving the quantity, relevance and quality of these studies. A better understanding of the
pharmacokinetic properties of antimalarials and a more clear definition of what constitutes "therapeutic drug levels"
would allow more precise use of the term "antimalarial resistance", as it would indicate when treatment failure is not
caused by intrinsic parasite resistance but is instead the result of inadequate drug levels. The clinical pharmacology
component of the WARN database can play a pivotal role in monitoring accurately for true antimalarial drug resistance
and promptly correcting sub-optimal dosage regimens to prevent these contributing to the emergence and spread of
antimalarial resistance.
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Background
The overall objective of the Worldwide Antimalarial
Resistance Network (WARN) database is to improve the
treatment of malaria, by informing drug selection and use
and providing a prompt warning of when treatment poli-
cies need changing [1]. This database should include data
on the clinical pharmacology of antimalarial drugs in
addition to their therapeutic efficacy, and the molecular
and in vitro markers of resistance. The clinical pharmacol-
ogy component of the database is essential to ensure opti-
mal dosing with currently available and newly introduced
antimalarial drugs through defining the correlation
between drug concentration and clinical and parasitolog-
ical response. This requires three key questions to be
answered: firstly, what is the profile of "therapeutic" drug
concentrations that needs to be sustained to eradicate the
plasmodial biomass? Secondly, are these drug concentra-
tions over time being achieved in the majority of all target
groups, including infants, pregnant women, and those
with prevalent co-morbid diseases (especially HIV/AIDS,
malnutrition) or are there important sub-groups being
under (or over) dosed? For example inadequate drug lev-
els have been repeatedly found in pregnant women and
young children [2-8]. Despite the antimalarial drug con-
centrations often being approximately half of those con-
sidered therapeutic, there has not yet been any dosage
regimen adjustment made to ensure that these vulnerable
populations are adequately dosed. Third, if current dosing
is found to be sub-optimal, can the regimen be adjusted
safely to ensure therapeutic dosing?
The determinants of therapeutic response are multi-facto-
rial. The ability of available antimalarial pharmacokinetic
data to inform optimal dosing is constrained by the small
number of patients studied, with even fewer (if any) stud-
ies conducted in the most vulnerable populations. The
variability in biological matrix (plasma, venous whole
blood, venous capillary blood), analytical methodology
used and the marked inter-individual pharmacokinetic
variation of some antimalarials (e.g. artemisinins) create
further challenges, in particular the need for effective
quality control of laboratory assays of drug concentrations
in biological samples, particularly blood – the site of
action of antimalarials. In the past, some attempts at
standardization were made without much success. Now
that a global database on the clinical pharmacology of
antimalarials is being planned, it is the appropriate time
to consolidate effort in this field. Individual pharmacoki-
netic studies are almost invariably underpowered in char-
acterising the factors that influence antimalarial
pharmacokinetic parameters. By pooling all available
pharmacokinetic data, while paying careful attention to
the methodology used, the limitation of small (and thus
underpowered) individual studies may be overcome and
the factors that contribute to inter-individual variability in
pharmacokinetic parameters defined. Similarly if there
were important drug-concentration related toxicities,
which could well have been missed due to the paucity of
the available data, these could be best recognized through
this database.
A better understanding of the pharmacokinetic properties
of antimalarials and a more clear definition of therapeutic
drug levels would allow more appropriate use of the term
"antimalarial resistance", as it would indicate when treat-
ment failure is not caused by parasite resistance but is the
result of inadequate drug levels, through sub-optimal dos-
ing, poor adherence, poor quality of the antimalarial,
poor absorption or poor metabolism to the active metab-
olite (for example with amodiaquine [9,10]). The clinical
pharmacology component of the WARN plays a pivotal
role in accurately monitoring for true antimalarial drug
resistance and promptly correcting sub-optimal dosage
regimens to prevent these contributing to the spread of
antimalarial resistance.
Objectives
The main objective of the clinical pharmacology compo-
nent of this database is to ensure rational use and optimal
dosing regimens in all target groups for currently available
and newly introduced antimalarial drugs. Achieving this
objective requires an understanding of the pharmacoki-
netic profile of each important component antimalarial
(including active metabolites) in each target group,
including infants, pregnant women, those with co-mor-
bid disease (especially HIV/AIDS, tuberculosis and mal-
nutrition). However, merely describing pharmacokinetic
parameters in each target population would not be
enough to optimize dosage regimens, as this requires a
clear definition of "therapeutic drug levels", i.e. the phar-
macokinetic parameters required to achieve an adequate
clinical and parasitological response (ACPR), specifically
in non-immune patients. The efficient analysis of the glo-
bal database will facilitate prompt recognition of:
1. target populations in whom a substantial proportion
fail to achieve therapeutic drug concentrations
2. target populations in which pharmacokinetic data on
key antimalarials are lacking or are inadequate
3. when or where the recommended dose results in a sub-
stantial number of treatment failures, despite achieving
drug concentrations that were previously defined as "ther-
apeutic", and whether this problem can be safely
addressed by increasing the dose, or whether a change in
policy is required.
4. Geographic variations which might have genetic or
environmental origins.Malaria Journal 2007, 6:122 http://www.biomedcentral.com/1475-2875/6/122
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In addition to the potential of the database to support
optimization of dosage regimens, it creates the opportu-
nity to simplify regimens based on age or weight/height,
and even to explore the potential of using pharmacoki-
netic measures to assess adherence. Importantly, by better
defining these information needs and criteria of accepta-
bility of pharmacokinetic-pharmacodynamic studies, the
database should contribute to improving the quantity, rel-
evance and quality of subsequent studies.
Challenges
Access to unpublished data
There are considerable obstacles that need to be overcome
to achieve the ambitious objectives of the clinical pharma-
cology component of the WARN database. These include
the paucity of published pharmacokinetic studies. These
have generally been small detailed studies conducted in
too few patients to inform rational optimal dosing regi-
mens. Some pharmacokinetic data (particularly the stud-
ies conducted during drug development) are not in the
public domain. These data are held by the manufacturer,
both commercial pharmaceutical companies and increas-
ingly by non-governmental organizations and Public-Pri-
vate Partnerships, such as the Medicines for Malaria
Venture (MMV) and the Drugs for Neglected Diseases Ini-
tiative (DNDi). It is in the interest of public health that
such data, and other unpublished pharmacokinetic data,
is rapidly included in the WARN Clinical Pharmacology
Database where it may be freely accessed. This requires
that obstacles to such groups contributing their data to the
database are identified, and true partnership between
stakeholders established to resolve how these obstacles
can be overcome. Given the limited PK data currently
available, it is considered advantageous that all available
pharmacokinetic data, despite their limitations, be
included in the WARN Clinical Pharmacology Database
and that the subsequent analysis be used to determine
which results are consistent, both in terms of pharmacok-
inetic parameters and factors that influence these.
Neglected populations
Most pharmacokinetic studies are conducted in healthy
volunteers and adult patients, with the most vulnerable
populations (infants, pregnant women, those with HIV/
AIDS co-morbidity, malnourished patients) systemati-
cally excluded from these studies. Researchers and funders
need to be encouraged to address these gaps urgently,
given the substantial impact that under-dosing of these
vulnerable groups would have on malaria morbidity and
mortality and on the selection and spread of antimalarial
resistance. Similarly, standard dosage regimens may be
associated with toxic drug levels being achieved in other
vulnerable populations.
Quality assurance and quality control
The main limitation in pooling individual patient data is
the variability in assay and analysis methodology between
pharmacokinetic studies. Another limitation is if different
biological matrices are used for different studies. There are
not always straightforward concentration relationships
between different matrices. This complicates the compar-
ison of results from different laboratories and studies, and
may invalidate pooling of data and meta-analysis of
results. It may be impossible to know whether the phar-
macokinetic properties in study populations actually dif-
fer or whether apparent differences merely reflect
variability in the accuracy of the methods used. This can
be addressed through method standardization or prefera-
bly, for more stable antimalarials, by the establishment of
a quality assurance process where blinded samples are
sent to all participating laboratories and the results of
their assays compared with the drug concentrations meas-
ured by the reference laboratories. This would be essential
even for laboratories that have ISO accreditation or Good
Laboratory Practice certification. Similar Quality Control
schemes operate in other disciplines such as haematology,
biochemistry, and immunology. Global participation in
this scheme would be facilitated by availability of a field
guide (Standard Operating Procedures) for sample collec-
tion and storage, core protocols for pharmacokinetic
(pharmacodynamic studies), a pharmacopoeia of vali-
dated antimalarial drug assays (including regression mod-
els), and regional repositories able to supply laboratories
with reference pure antimalarial compounds, their metab-
olites and appropriate internal standards, and analytical
grade reagents (Appendix 1). It is important to standard-
ize not only the actual assay methodology but also the
standard/calibration curve relationship (i.e. regression
model) for quantification of unknown samples (see Fig-
ure 1). Similarly, guidelines are needed on the statistical
methods recommended for the analysis of pharmacoki-
netic data and capacity building of statisticians in malaria
endemic countries, particularly for the complex and time
consuming population pharmacokinetic analyses. Future
comparisons of pharmacokinetic studies would be facili-
tated by defining the minimum requirements for publish-
ing antimalarial pharmacokinetic studies.
The assay methodology is a key determinant of the accu-
racy of the results. In most cases Mass Spectrometric and
High Performance Liquid Chromatographic assays are
more likely to give reliable results than the Bioassay or
simple chemical or chromatographic methods, although
early Mass Spectrometric assays may have been compro-
mised by ion suppression [11]. Validity can be further
assessed by considering the reported recovery, coefficients
of variation (for quality control samples), back-calculated
concentrations for calibration standards, regression
model, stability, lower limits of quantification, sampleMalaria Journal 2007, 6:122 http://www.biomedcentral.com/1475-2875/6/122
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handling, volume of sample, biological matrix, anticoag-
ulant, duplicate assay, inter- and intra-assay variability,
and data handling. These factors could be used to rate the
quality of the pharmacokinetic data on a scale of 0 (poor)
to 3 (excellent), rather than including each individual var-
iable in the database. This could be done through the
development of an algorithm for rating validity for each
assay. Alternatively, a statistical approach to pooled data
can be taken to determine whether the laboratory identity
is an independent predictor of pharmacokinetic parame-
ters, once other known PK determinants are adjusted for.
Structure and content of the WARN Clinical 
Pharmacology Database
The WARN Clinical Pharmacology Database will have two
components: one summarizing all available pharmacoki-
netic (pharmacodynamic) data and the second containing
individual patient data on the pharmacokinetics (and
where available pharmacodynamics) of antimalarial
drugs. The available summary pharmacokinetic data will
be collated into an open access database as rapidly as pos-
sible, to inform the finalising of the structure of the indi-
vidual-patient database and identify gaps in the data (e.g.
vulnerable target populations for whom no pharmacoki-
netic data are currently available).
The most valuable, longer term contribution of the Clini-
cal Pharmacology component of a global antimalarial
drug resistance database is likely to be individual patient
data, as this should overcome the problem of small under-
powered individual pharmacokinetic studies and ulti-
mately is essential for making progress toward defining in
vivo therapeutic ranges and modelling resistance, both of
which are needed to optimize useful therapeutic life of the
few available antimalarial drugs. Linking individual
patient pharmacokinetic data with the demographics of
those studied will allow us to define the determinants of
these pharmacokinetic parameters.
The database needs to include study patient characteris-
tics, methodology for determining the pharmacokinetics
of each antimalarial, and where available, antimalarial
treatment response (pharmacodynamics). The primary
and secondary variables in the database are summarized
in Tables 1 and 2.
Patient characteristics
A thorough understanding of what factors influence anti-
malarial drug exposure would be facilitated by the inclu-
sion of all pharmacokinetic studies in the database. The
effect of disease would be assessed by comparison of phar-
macokinetics in normal healthy volunteers with malaria
patients. The effect of disease severity would be explored
by comparing parasitaemic patients with asymptomatic,
uncomplicated, moderately severe and severe malaria –
with careful definition of these classifications. The phar-
macokinetics of antimalarials administered as intermit-
tent preventive therapy to pregnant women, infants and
children, needs to be determined specifically as they may
differ substantially both from those in normal healthy
volunteers and in non-pregnant adult patients with
malaria. As vast quantities of antimalarials, particularly
chloroquine, are administered to patients infected with
non-falciparum malaria parasites, particularly Plasmodium
vivax, pharmacokinetic studies in these populations are
essential for optimizing antimalarial drug use.
Given marked variability in the quality of antimalarials
available [12], it is essential to specify the details regarding
the antimalarial drug used in each pharmacokinetic study
including manufacturer, source, expiry date (and ideally
batch number and reference method used to ensure tablet
content). It would be desirable also to include testing of
the actual content of antimalarial drug in several tablets
(or ampoules etc.) with standardized methodology. Simi-
larly the exact method of drug administration needs to be
documented, noting which of the doses were supervised,
how tablets were administered to young children (as these
are often crushed in sugar solution, jam or banana which
may alter bioavailability) and, if relevant (e.g. lumefan-
trine), the quantity of fat administered together with the
antimalarial dose. The route and time(s) of administra-
tion and actual dose administered, including when doses
are repeated following vomiting, need to be specified.
Patients in pharmacokinetic studies who require repeated
dosing (usually following vomiting) should continue to
have drug concentrations measured throughout the fol-
Parameters for modeling calibration curves Figure 1
Parameters for modeling calibration curves.
• Field guide for pharmacokinetic sample collection and storage
• Core protocols for pharmacokinetic studies
• Pharmacopoeia of validated antimalarial drug assays
• Regional repositories able to supply laboratories with reference pure antimalarial
compounds, their metabolites and appropriate internal standards, and analytical
grade reagents.
• Designated reference analytical laboratories to ensure quality control in
pharmacokinetic assays (including sending blinded samples to regional
laboratories regularly) and to assay samples from study sites without access to
reliable analytical laboratories.
• Guidelines on the statistical methods recommended for pharmacokinetic analyses
• Minimum reporting recommendations for publishing antimalarial
pharmacokinetic studiesMalaria Journal 2007, 6:122 http://www.biomedcentral.com/1475-2875/6/122
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low up period, provided the time and dose of repeated
administration is recorded accurately. Current policies to
exclude these patients from further studies preclude evi-
dence-based guidelines for the management of these
patients, even though vomiting is commonly reported
among children with malaria. The weight of the patient is
required to specify the mg per kg dose administered, and
can identify those patients that are likely to be malnour-
ished or obese; this assessment can be made more accu-
rate by inclusion of height in the database as this would
allow for the calculation of Body Mass Indices (BMIs).
Age and weight influence pharmacokinetics, so character-
ization of these effects is necessary for the development of
simplified yet effective dosage regimens by age category.
In areas of moderate and high intensity malaria transmis-
sion, age is an important surrogate indicator of the prob-
ability of acquired partial immunity, which needs to be
included when assessing the pharmacokinetic-pharmaco-
dynamic relationship. Similarly, pregnancy status (and
trimester) needs to be included as immunity is reduced
during pregnancy, and physiological changes during preg-
nancy are likely to alter the pharmacokinetics of most
antimalarials. A recent history of vomiting or diarrhoea
prior to oral treatment may be associated with lower bio-
availability [13]. Recording of co-morbid diseases, partic-
ularly HIV/AIDS and malnutrition, would identify
whether any alteration in treatment dosage or policy is
indicated for patients with these conditions.
Pharmacokinetic studies with commonly used concomi-
tant medication (particularly antiretroviral treatments,
anti-emetics, antihistamines) will identify clinically sig-
nificant drug interactions, while administration of, for
example, antipyretics or antibiotics with antimalarial
activity needs to be documented for reliable interpretation
of the therapeutic response. Variations in antimalarial
pharmacokinetics by region or ethnic group might point
to potential pharmacogenetic differences in drug metabo-
lism indicating when pharmacogenomic studies would be
useful. Useful supporting laboratory data include meas-
ures of haematocrit, bilirubin, creatinine and albumin.
Table 2: Secondary parameters to be included in WARN Pharmacokinetic Database, if available.
Patient characteristics Antimalarial Methodology Pharmacokinetic parameters
Height Directly Observed Therapy
(DOT) [1]
Method for separating free drug Primary parameters: Absorption rate 
constant (Ka); Elimination Rate constant 
(Ke), Volume of distribution; Clearance 
rate.
Vomiting Batch number & Expiry Date Sample handling Secondary parameters: Cmax, tmax, 
elimination half-life;
Diarrhoea Method of Administration [2] Total vs free drug
Baseline parasite density Co-administration [3] Metabolites
Haematocrit, Bilirubin, Creatinine, 
Albumin (alpha1 glycoprotein, 
lipoprotein)
Ethnicity
Footnotes to Table 2
DOT: All doses supervised; First dose supervised; Unsupervised.
2. Administration: Whole tablets; Divided tablets; Crushed tablets.
3. Co-administration: Water; Fat content; Sugar water; Concomitant medication
Table 1: Primary parameters to be included in WARN Pharmacokinetic Database
Patient characteristics Antimalarial Methodology Pharmacokinetic parameters
Malaria status [1] Generic name Sampling times (to include sampling on day of 
recurrence of parasitemia)
Day 7 concentration (median, IQR, 
range)
Age Dose (total) Sample Matrix (e.g. Venous blood, capillary blood, filter 
paper spot, breast milk, placenta, urine, saliva)
AUC (median, IQR, range)
Weight Manufacturer Assay method Pharmacokinetic model
Gender Route of administration Assay Validity [3]
Sample size Sample volume
Special Risk Group [2] Sample storage (temperature and duration)
Footnotes to Table 1
Malaria status: Healthy volunteer; Asymptomatic Pf malaria; Intermittent preventive treatment (IPT); Uncomplicated Pf malaria; Moderately 
severe malaria; Uncomplicated hyperparasitaemia; Severe malaria; Uncomplicated P. vivax malaria; Prophylaxis; Other non-malaria disease.
2. Special Risk Group: Pregnancy (trimester); Infants; Pre-school; Co-morbid disease (HIV/AIDS; Tuberculosis; malnourished; obese).
3. Assay Validity: Retrospective data: Validity rating; Prospective data: pre-defined QC requirementsMalaria Journal 2007, 6:122 http://www.biomedcentral.com/1475-2875/6/122
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Other proteins such as the main binding protein for basic
drugs alpha acid glycoprotein are relevant for quinine and
chloroquine, while artemisinins also bind to lipoproteins
[14-16].
Measuring drug concentrations over time
The selection of sample matrix (e.g. venous blood, capil-
lary blood, plasma, breast milk, placenta, urine) will
depend on the drug and the study context and objectives.
Capillary blood of fixed volume collected into calibrated
capillary tubes and dried on to filter paper is the most fea-
sible sample for use in field studies, and such assays have
been validated for chloroquine, quinine, halofantrine,
piperaquine, amodiaquine, sulphadoxine/pyrimeth-
amine, atovaquone, mefloquine and proguanil [7,17-23].
The accuracy of these assays depends on the filter paper
used (and its pre-treatment, when needed) and relies on
careful training to ensure, for example, an accurate vol-
ume of sample, avoiding diluting the sample with intersti-
tial tissue fluids by excessive squeezing of the patient's
finger, and preventing contamination by touching the fil-
ter paper after touching the study drug. A simple field
guide providing simple SOPs is needed to optimize sam-
ple collection and storage. Where protein binding is sub-
stantial, it is ideal to measure both total and free drug,
although this is not possible for whole blood spots dried
onto filter paper. Furthermore, the concentration of free
drug for drugs with substantial protein binding (i.e.
>99%) is very low and will thus in many cases be limited
by assay sensitivity. There are currently no validated assays
for capillary blood spots on filter paper for pyronaridine,
lumefantrine or the artemisinin derivatives.
The selection of sampling times depends on the pharma-
cokinetic properties, particularly the elimination half-life,
of each antimalarial drug, the context of the study and the
therapeutic objective of treatment. Although time to reach
therapeutic concentrations is of critical importance in
treating severe malaria, for the treatment of uncompli-
cated malaria, an adequate clinical and parasitological
response requires the persistence of levels that exceed the
minimum inhibitory concentration (a concentration
resulting in a parasite multiplication rate of <1/cycle) for
at least four 48-hour asexual blood cycles in non-immune
patients. The day 7 drug concentration has been shown to
be the most important single concentration, in terms of
correlation with the area under the concentration time
curve and or association with treatment response, for
lumefantrine, piperaquine, quinine, mefloquine and sul-
phadoxine-pyrimethamine [7,17,24-27]. As day 7 is a
routine visit in therapeutic efficacy studies [28], measur-
ing drug concentrations at least at this time point is rec-
ommended for all medium- to long acting drugs (i.e.
drugs with half-lives greater than 12 hrs). This requires
drug assays that are sensitive enough to quantify antima-
larial drug levels accurately at least until this time point.
Treatments with shorter elimination half-lives require
more frequent earlier sampling. Further pharmacokinetic
studies are needed to define optimal sampling times for
the treatment of P. vivax (and other non-falciparum spe-
cies).
The respective roles of conventional and population phar-
macokinetic approaches need to be considered when
selecting timing of sample collection. Intensive sampling
is needed initially for each antimalarial and in each
important target population. Subsequently, population
pharmacokinetics can be used to minimize the number of
times blood needs to be collected from an individual
patient, thereby allowing more patients to be included in
the study. Population pharmacokinetic analysis is com-
plex and time consuming, taking between six and 12
months per drug. Extensive capacity building (particularly
training in statistical modelling) is needed for population
pharmacokinetic modelling to be more widely used, par-
ticularly in malaria endemic countries. Occasionally, the
population pharmacokinetic approach will not succeed in
modelling the pharmacokinetics of a particular antimalar-
ial. Standardization in reporting will also be needed.
Given the skew distribution of most pharmacokinetic
parameters, these should preferably be reported as medi-
ans, inter-quartile ranges and ranges. Although summary
measures are most often reported, the extremes of the
range are more important in exploring the pharmacoki-
netic determinants of treatment failure and toxicity. This
creates need for accurate characterization of the variability
in of pharmacokinetic parameters.
Pharmacokinetic-pharmacodynamic 
relationships
Defining in vivo therapeutic levels requires analysing asso-
ciations between drug levels and the risk of recurrent par-
asitaemia, recrudescence and re-infection [29]. For those
antimalarials where the parasite mutations associated
with resistance have been defined, this analysis should be
stratified by genotype [30]. It is useful to determine the
drug level at the time of failure, even when this was not a
routine pharmacokinetic sampling time, although clinical
signs and symptoms at this time need to be recorded as ill-
ness itself may affect pharmacokinetic parameters, such as
the volume of distribution. Comparison of the pharma-
cokinetic parameters at the time of late clinical and late
parasitological failure can be used to measure this effect.
Population pharmacokinetics may be helpful to predict
what the antimalarial drug level was likely to have been
when parasitaemia became patent.
The association between drug exposure and the rate of
reduction in parasite density (Parasite reduction ratios
(PRRs), Parasite Clearance Times (PCTs), Time to clear-Malaria Journal 2007, 6:122 http://www.biomedcentral.com/1475-2875/6/122
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ance of 50% and 90% of parasites (PC50, PC90) are
expected to be the earliest measures for detecting sub-opti-
mal exposure to artemisinins and decreasing artemisinin
efficacy as these drugs uniquely affect ring stage clearance.
Monitoring the association between drug levels and post-
treatment fever is useful both as a determinant of some
pharmacokinetic parameters and as a secondary efficacy
endpoint; however, the use of antipyretics complicate the
interpretation of this association.
To define the upper limit of the therapeutic range, all
adverse events need to be recorded and related to drug
exposure. Particular attention should be paid to gastro-
intestinal disturbances following oral treatment as this
could reduce drug bioavailability. Recording of time to
vomiting and the effect of this on drug levels, including
when dosing is repeated following vomiting, is essential
to inform how patients who vomit after oral treatment
should be managed.
Lastly, a better understanding of how the pharmacoki-
netic profiles of various artemisinin-based combinations
influence gametocyte carriage and the selection of resist-
ant re-infections, would help to predict the therapeutic
life of an antimalarial. This could help inform the selec-
tion of treatment policies, and help drug developers prior-
itize development of new antimalarials that have the best
chance of remaining effective for longest.
Conclusion
The public health benefits of recent dramatic increases in
spending on antimalarials create a particular urgency for
ensuring that patients with malaria receive the best treat-
ment in the correct dose. The investment in a global clin-
ical pharmacology database would create a valuable
resource that would make a substantial contribution to
improving the treatment of malaria, which is currently
compromised by increasing antimalarial resistance and
the lack of pharmacokinetic data or sub-optimal dosing in
vulnerable populations, particularly pregnant women and
young children. The success of the database depends on
willingness to share all available pharmacokinetic data
and prompt, intelligent and unbiased analysis and inter-
pretation of the determinants of pharmacokinetic param-
eters and the association of these with therapeutic
response.
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Appendix 1: Tools to facilitate participation in 
Clinical Pharmacology Database
❍ Field guide for pharmacokinetic sample collection and
storage.
❍ Core protocols for pharmacokinetic studies.
❍ Pharmacopoeia of validated antimalarial drug assays.
❍ Regional repositories able to supply laboratories with
reference pure antimalarial compounds, their metabolites
and appropriate internal standards, and analytical grade
reagents.
❍ Designated reference analytical laboratories to ensure
quality control in pharmacokinetic assays (including
sending blinded samples to regional laboratories regu-
larly) and to assay samples from study sites without access
to reliable analytical laboratories.
❍ Guidelines on the statistical methods recommended for
pharmacokinetic analyses.
❍ Minimum reporting recommendations for publishing
antimalarial pharmacokinetic studies
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